NewTimeSpace News:As of 14:25 on March 3, 2026, the CSI Medical Health Index (000933) dropped 1.83%. Its constituent stocks saw a mixed performance of gains and losses: NHU Co., Ltd. led the gains with a rise of 4.55%, Jiu'an Medical increased by 4.05% and New Industries Biomedical Engineering rose 3.38%; Meinian Onehealth Healthcare Group Co., Ltd. led the declines with a drop of 9.50%, BeiGene fell 6.55% and Junshi Biosciences decreased by 6.41%. TheChina Universal CSI Health Care ETF (159929) fell 1.88%, with the latest price at 1.3 yuan. Over a longer period, as of March 2, 2026, theChina Universal CSI Health Care ETF had a cumulative increase of 5.56% in the past year. (The stocks listed above are only constituent stocks of the index and do not constitute any specific investment recommendation.)

In terms of liquidity, theChina Universal CSI Health Care ETF recorded an intraday turnover rate of 3.98% with a trading volume of 96.8571 million yuan. As of March 2, its average daily trading volume in the past year stood at 76.6649 million yuan.

In terms of scale, the latest size of theChina Universal CSI Health Care ETF reached 2.445 billion yuan. (Data source: Wind)

In terms of capital net inflow, theChina Universal CSI Health Care ETF has seen continuous capital net inflows for three consecutive days, with the maximum single-day net inflow hitting 11.9636 million yuan, a total net inflow of 16.0186 million yuan and a daily average net inflow of 5.3395 million yuan. (Data source: Wind)

Data showed that leveraged funds have been continuously building positions in the ETF. The margin net purchase of theChina Universal CSI Health Care ETF in the previous trading day reached 2.3634 million yuan, with the latest margin balance standing at 79.5391 million yuan. (Data source: Wind)

As of March 2, the net asset value of theChina Universal CSI Health Care ETF has risen 5.23% in the past year. In terms of profitability, as of March 2, 2026, since its establishment, theChina Universal CSI Health Care ETF has achieved a maximum monthly return of 23.11%, a longest streak of 8 consecutive monthly gains with a cumulative increase of 63.16% during the period, a ratio of up months to down months of 79:71 and an average return of 5.34% in up months. The historical probability of making a profit with a 3-year holding period is 61.84%. As of March 2, 2026, theChina Universal CSI Health Care ETF has delivered an annualized excess return over the benchmark of 1.21% in the past two years.

In terms of drawdown, as of March 2, 2026, the maximum drawdown of theChina Universal CSI Health Care ETF since the start of the year was 8.57%, with a relative benchmark drawdown of 0.04%.

In terms of fees, theChina Universal CSI Health Care ETF has a management fee rate of 0.50% and a custodian fee rate of 0.10%.

In terms of tracking accuracy, as of March 2, 2026, the tracking error of theChina Universal CSI Health Care ETF in the past two months was 0.012%.

Notably, the CSI Medical Health Index tracked by the fund is at a historically low valuation, with the latest price-to-book ratio (PB) standing at 3.12 times, lower than that in more than 87.81% of the time since the index was established, representing a prominent valuation cost performance.

TheChina Universal CSI Health Care ETF closely tracks the CSI Medical Health Index. To reflect the overall performance of securities of companies in different industries within the CSI 800 Index sample and provide an analytical tool for investors, the CSI 800 Index sample is divided into 11 first-level industries and 35 second-level industries according to the CSI Industry Classification. Indices are then compiled with all securities in each first-level and second-level industry as samples, forming the CSI 800 Industry Indices.

Data showed that as of February 27, 2026, the top 10 weight stocks of the CSI Medical Health Index (000933) were WuXi AppTec Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Mindray Medical International Limited, United Imaging Healthcare Co., Ltd., Yunnan Baiyao Group Co., Ltd., Aier Eye Hospital Group Co., Ltd., Zhangzhou Pientzehuang Pharmaceutical Co., Ltd., NHU Co., Ltd., Sichuan Kelun Pharmaceutical Co., Ltd. and Shanghai Fosun Pharmaceutical (Group) Co., Ltd., accounting for a total of 43.48% of the index weight. (The stocks listed above are only constituent stocks of the index and do not constitute any specific investment recommendation.)

Huafu Securities stated that the performance of the pharmaceutical manufacturing industry was under pressure in 2025 but with structural differentiation: chemical pharmaceuticals achieved double growth in net profit by virtue of innovation and overseas expansion, while biological products and traditional Chinese medicine declined due to saturated demand and the impact of volume-based procurement. Innovation has become the core driver, with the number of approved new drugs hitting a record high in 2025 and R&D resources concentrating on cutting-edge fields. Looking ahead to 2026, population aging underpins rigid demand, yet overseas regulatory barriers and geopolitics are forcing enterprises to transform from "product globalization" to "capability globalization".

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.